menu search

Should you still buy the nasdaq's best-performing october stocks?

Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that...

November 3, 2023, 5:20 am

Merck to present latest research from oncology portfolio at esmo 2023

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research ...

October 16, 2023, 2:00 am

Merck's (mrk) meets goal in muscle-invasive bladder cancer study

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain pati...

October 6, 2023, 1:32 pm

Merck blockbuster shows promise in bladder cancer

Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster cancer drug Keytruda in people with cer...

October 5, 2023, 8:43 am

Merck reports positive results in late-stage trial of keytruda as treatment for bladder cancer

Merck & Co. Inc. MRK, +0.39% said Thursday a late-stage trial of its cancer treatment Keytruda met its main goal of disease-free survival for patients...

October 5, 2023, 7:26 am

Seagen's (sgen) combo drug meets goals in bladder cancer study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metas...

September 25, 2023, 12:01 pm

Seagen-merck bladder cancer treatment shows positive results; seagen shares jump

Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experi...

September 22, 2023, 12:40 pm

Why shares of immunitybio jumped this week

The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company sto...

September 15, 2023, 12:52 pm

Bicycle (bcyc) to begin pivotal bladder cancer study, stock up

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder...

September 12, 2023, 9:05 am

J&j (jnj) seeks approval for bladder cancer drug in europe

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the...

September 11, 2023, 1:32 pm

Royalty pharma: we continue to like the strategy and sell-off is overdone

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnersh...

September 5, 2023, 11:24 pm

Urogen pharma (urgn) stock surges 89% in a month: here's why

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladd...

August 18, 2023, 2:49 pm

Why shares of axonics rose friday

Axonics is a medical device company that focuses on bladder and bowel dysfunction therapies. The compan...

July 28, 2023, 12:46 pm

Bristol myers' bladder cancer drug meets goal in late stage sub-study

Bristol-Myers Squibb Co said on Tuesday its drug in combination with chemotherapy met a dual main goal in a late-stage trial in patients with a type o...

July 11, 2023, 7:19 am

Fda rejects immunitybio's (ibrx) bladder cancer therapy filing

FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder...

May 12, 2023, 12:57 pm

Immunitybio: anktiva rejection heightens financial urgency

ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive ...

May 12, 2023, 5:20 am

Non-muscle invasive bladder cancer therapeutics market size to surpass us$ 9.8 billion at a cagr of 14.8% between 2023 to 2033| persistence market research

Growing Cancer Patient Pool and Increased Accessibility to Advanced Therapies Driving Non-muscle Invasive blad...

May 11, 2023, 1:46 pm

2 pharma stocks in focus on fda buzz

Immunitybio Inc (NASDAQ:IBRX) stockĀ is crumbling today, down 52.1% at $2.98 at last glance, and earlier as low as $2.45, after the U.S. Food and Drug...

May 11, 2023, 10:55 am

Immunitybio in dramatic selloff as fda puts bladder cancer treatment on hold

ImmunityBio Inc shares were sinking fast on Thursday morning after receiving notice from the US Food and Drug Administration that its Biologics Licens...

May 11, 2023, 10:15 am

Immunitybio stock loses more than half its value after disclosing fda can't approve the bla for its cancer treatment in its present form

Shares of ImmunityBio Inc. IBRX plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclos...

May 11, 2023, 9:16 am


Search within

Pages Search Results: